Remote monitoring and patient self-monitoring can drive CPAP adherence
for people with sleep apnea, according to research presented by ResMed
(NYSE: RMD) (ASX: RMD) at the American Thoracic Society’s 2019 ATS
Average adherence to PAP (positive airway pressure), the gold standard
for treating sleep apnea, is approximately 50 percent when using legacy
technology with no cloud connectivity or remote monitoring capabilities.
According to the new study, researchers found significantly higher rates
when they evaluated patients on 100% cloud-connectable devices that
enable remote monitoring: more than 31,000 Brazilians, 17,000 Mexicans,
and 4.1 million Americans.
|Percent of study|
|PAP adherence (all||Remotely and|
“These results equate a strong endorsement for remote and
self-monitoring technology,” said study coauthor and ResMed Chief
Medical Officer Carlos M. Nunez, M.D. “Despite different healthcare
systems, financial and social issues, patients in all three countries
have reached above-average adherence rates when treated with 100%
cloud-connectable PAP devices.”
Researchers also urge clinicians to enroll their PAP patients in a
self-monitoring program like myAir, ResMed’s patient engagement app.
While 26 percent of U.S. patients in this study had registered for
myAir, only 8.1 percent of Brazilian patients and 2.8 percent of Mexican
PAP adherence was defined for this study using the U.S. Centers for
Medicare and Medicaid Services definition: using PAP usage of four
hours per night for 70 percent of nights in a 30-day span within the
first 90 days of therapy.
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions that
treat and keep people out of the hospital, empowering them to live
healthier, higher-quality lives. Our cloud-connected medical devices
transform care for people with sleep apnea, COPD and other chronic
diseases. Our comprehensive out-of-hospital software platforms support
the professionals and caregivers who help people stay healthy in the
home or care setting of their choice. By enabling better care, we
improve quality of life, reduce the impact of chronic disease and lower
costs for consumers and healthcare systems in more than 120
countries. To learn more, visit ResMed.com
and follow @ResMed.